5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.
about
Role of solute carriers in response to anticancer drugsChemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of actionSlug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatmentAbnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase geneGeneration and characterization of a human single-chain fragment variable (scFv) antibody against cytosine deaminase from yeast.In Vivo Chemoprotective Activity of Bovine Dialyzable Leukocyte Extract in Mouse Bone Marrow Cells against Damage Induced by 5-Fluorouracil.Recent trends in targeted anticancer prodrug and conjugate design.Reduced Autophagy in 5-Fluorouracil Resistant Colon Cancer CellsState of Art of Cancer Pharmacogenomics in Latin American Populations.A case of 5-fluorouracil induced encephalopathy.A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells.Panax ginseng modulates cytokines in bone marrow toxicity and myelopoiesis: ginsenoside Rg1 partially supports myelopoiesis5-Fluorouracil derivatives: a patent review.Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity.The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stabilityEvaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?Antimetabolite incorporation into DNA: structural and thermodynamic basis for anticancer activity.Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver.Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells.Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency.Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model.Gold-containing indoles as anticancer agents that potentiate the cytotoxic effects of ionizing radiation.An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant Staphylococcus aureus (MRSA)Use of thymine limitation and thymine starvation to study bacterial physiology and cytology.Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenatesDIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience.5-Fluorouracil: mechanisms of resistance and reversal strategies.Radiation- and photo-induced activation of 5-fluorouracil prodrugs as a strategy for the selective treatment of solid tumors.A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.Pharmacology and pharmacogenetics of chemotherapeutic agents.The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.Symptomatic 5-fluorouracil-induced sinus bradycardia.Pharmacogenomics of fluorouracil -based chemotherapy toxicity.5-Fluorouracil derivatives: a patent review (2012 - 2014).Anticancer effects of seaweed compounds fucoxanthin and phloroglucinol, alone and in combination with 5-fluorouracil in colon cells.Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Self-assembly of a 5-fluorouracil-dipeptide hydrogel.
P2860
Q27027625-8BB14E4A-E033-44EF-867C-25507276967FQ27693179-87A6B1FF-C7C6-4D34-B97E-4D61EE62DCCDQ28546067-1667DD78-F5DB-4D1D-B95E-1CEC52B5536EQ28592018-073A35FB-F540-4AEF-94AD-6E411DF21488Q33368449-980E1938-65F3-4C16-9165-3967F9495354Q33432319-6A087232-9B66-4A37-A173-AD97C27FA946Q33573762-F2C0E8D2-A1AA-4BB8-8A91-17F9C7145456Q33655918-2C896C85-CA8B-44F1-A940-447021DB2DFAQ33838298-BF496915-2EE4-4D2A-9C16-0BEC02475762Q33979979-33AE1097-3753-4EE8-B305-79BD079F8EE9Q34043011-088EB2E6-2DBD-4DBC-B7DD-FB735E531AA1Q34241632-F35AAEAD-2B76-4CFD-BF39-20EBEDDCAE99Q34253978-79D1A681-76E1-4233-9F28-30E6D87BF6FBQ34522413-DE57BAB6-189D-488B-85C1-C6BAF3EC7D2EQ34570055-BD60D69C-1C9F-483F-A1CD-35DE9769EF5FQ34847802-DAF5B2ED-B2A9-48D9-9A3F-2E00F913D30BQ34850202-24824713-3349-40A5-805A-12798FDA3EEDQ35056479-25A76A72-4FC8-4C09-A314-8B54845AB918Q35109800-F8C66477-C29C-464D-A9C3-5EF71AB1A43DQ35376189-20FED0B5-FB10-4DE5-8A5B-F54BF9D2BD07Q35556789-A351DB22-54BF-4490-AE3E-308F5BED329AQ35584647-EC8501A9-B9DD-4894-B3F8-45FC8AD70B49Q35788266-869517CA-AB0E-48C2-BDE6-D89D8D50C151Q35889822-4FEC9212-8DA1-44BA-934F-F64FACA84335Q35973180-129B86A3-11A1-4E44-AFDC-818010DD0799Q36399150-211457CE-850C-4579-8649-33C0985D63D2Q36631747-1C28CAFF-0EEC-42C6-983B-72A9B8EA3FCDQ36927562-6CA10781-B98C-4B0F-86B8-FC2E247A2E91Q36936972-65568154-1947-4B58-A986-198A2019E9C8Q37270356-B1A58294-6EEB-4466-9D41-FB9B40A74048Q37284613-31F980BB-C8B1-4A9B-B4E3-E9BDBD76320AQ37387427-24CAEE26-DB2B-404E-BCE3-96CDB6A9B3A3Q37500096-34D08EFC-58E3-4D3B-87EB-D310D7243994Q37617635-56D7C7A6-69E4-4492-9E96-6036EF22DDAEQ37901554-41712284-3587-45BF-BCAB-EDAC4B0A1201Q38387640-9F4E7FE2-3B5E-423A-8E80-AFB87D110303Q38545641-72D043E5-4E40-461A-ABDC-2A185EEC2346Q38693910-67D7AC21-A2A1-4535-A0ED-AD83578FDBAEQ38740840-8B84D4F9-9E49-425C-9044-C01CF395F1B8Q38784753-4B7A4CD0-C2DF-45EB-9620-A03DA0109119
P2860
5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
5-Fluorouracil: forty-plus and ...... ical and clinical development.
@ast
5-Fluorouracil: forty-plus and ...... ical and clinical development.
@en
type
label
5-Fluorouracil: forty-plus and ...... ical and clinical development.
@ast
5-Fluorouracil: forty-plus and ...... ical and clinical development.
@en
prefLabel
5-Fluorouracil: forty-plus and ...... ical and clinical development.
@ast
5-Fluorouracil: forty-plus and ...... ical and clinical development.
@en
P356
P1476
5-Fluorouracil: forty-plus and ...... ical and clinical development.
@en
P2093
P2888
P304
P356
10.1023/A:1006416410198
P577
2000-11-01T00:00:00Z
P6179
1017158719